JAZZ

#3333
Jazz Pharmaceuticals plc - Ordinary Shares
2.3 6 USD
+0.47%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
2.36
2.36
Rango anual
2.36
243.32
Cambio diario
+0.47%
Variación mensual
-98.83%
Variación en los últimos 6 meses
-98.64%
Cambio anual
-98.31%
Cierres anteriores
2.3 5
Open
2.3 6
Mínimo
2.3 6
High
2.3 6
Volumen
137
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 148.38 M
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-29.11
Relación precio/flujo de caja
2.43

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Noticias